Could this stock compete with Elon’s Neurolink? 🧠

Look at this price chart!                                                                                                                                                                                                                                                                                                                                                                                                                 March 04, 2024 Could this stock compete with Elon’s Neurolink? 🧠Look at this price chart! *Promoted by Sica Media NMTC is a Cutting-Edge Technology Stock That is Flashing a Strong “GO” Signal Right Now Happy Monday! I nerded out this weekend 🤓. I went through lots of investor presentations, looked at hundreds of stock charts, and watched hours of trading videos. I am feeling super-sharp and dialed into this week ahead… I hope you are, too! For my biggest takeaway, I will be especially looking at small-cap, biotech, gold and semiconductor stocks this week! Those appear to have the biggest momentum trends behind them right now. With the success we have been seeing with smaller stocks lately, I am pumped to get this week kicked off with another awesome idea – so let’s get to it!  The stock I’m pulling up on my platform right now is NeuroOne Medical (NMTC). As I was pouring over charts this weekend, one thing that stood out to me was this tiny medical device maker (really awesome technology, too. I’ll get to that in a minute). ✅ As a small-cap and a biotech stock, NMTC checks off two of the major trends I see for this week. After a series of back-and-forth price moves over the last couple of months, NMTC has quietly started to build a base above the “magical $1 level” and has already started to climb out of that range. As you can see below, NMTC just fired off a “Gamma Trigger” signal on Friday. This could be the start of a very powerful move. I think today will be a crucial day for NMTC. In the chart below, you’ll see where I think the recent support/resistance levels have been. If this “Gamma Trigger” move continues to carry NMTC higher, I think it is very important to keep an eye on the $1.40 level, which has shown to be resistance lately.  If that is broken through convincingly, it could then act as a new support level. The cool thing is that after the $1.40 level, the next serious resistance point is all the way at $2, which NMTC has tested a few times in the last year. However, if the move fails, I would keep a close eye on $1.05, which has been the support level on the downside. This is an incredible risk/reward setup to pay close attention to right now. NMTC has shown that it can make some highly sustained moves from these low levels. In November / December, NMTC rallied from $.90 to $2.00 (a move over 120% higher) in just a few weeks’ time. In July, NMTC made a similar move when it made a 100% move over a few days. If this current move is anything similar to that, we could be in the very early stages. I would also note that this stock has moved extremely quickly in the opening stages of those rallies. I think it is important that you get NMTC on your radar right away so you don’t miss watching any of the action today. While the price chart is obviously fantastic looking to me, I find the technology that the company is working on to be equally fascinating. It reminds me of Elon’s Neurolink company. Let me explain.  NeuroOne Medical Technologies Corp (NMTC) is a medical technology developer of electrodes designed to diagnose and treat a variety of neurological conditions. Despite being a relatively small company, NMTC has received FDA clearance for three of its devices and has forged powerful partnerships with the likes of the Mayo Clinic — the nation’s top-ranked hospital. NMTC’s clinical partnership with the Mayo Clinic began in 2017, and the first commercial human use of one of NMTC’s electrodes was performed at the Mayo Clinic in November 2020. Today, the Mayo Clinic is a top shareholder in NMTC and its leading neurologist, Dr. Greg Worrell, chairs the company’s Scientific Advisory Board. [According to the company]( this collaboration with the Mayo Clinic has produced “disruptive next-generation diagnostic electrodes advancing a new era in neuroscience.” The company’s three FDA-cleared devices are: Evo® Cortical Electrode - A device that can “monitor, record and stimulate the surface of the brain for up to 30 days.” It’s up to seven times thinner and eight times lighter than the legacy silicon-based electrodes. These electrodes are designed to cause less trauma to the brain and therefore generate a decreased immune response, which can interfere with electrode readings. Evo® sEEG Electrode - An advanced diagnostic device for seizure detection. It’s designed to be less invasive and to reduce the risk of “plunging” and brain damage. The company says this electrode offers “proven placement accuracy and outstanding signal quality,” allowing doctors to “capture the vital data [they] need to support more confident diagnoses.” OneRF™ Therapeutic Ablation Electrode System - This is a technology that pairs with the sEEG electrodes to provide therapeutic functionality in addition to the diagnostic. Cleared by the FDA in December, this system creates radiofrequency (“RF”) lesions in nervous tissue for use in neurosurgical procedures. NMTC formed a strategic partnership in July 2020 with Zimmer Biomet (ZBH, ~$25B market cap) — “a worldwide leader in robotic technology used in minimally invasive neurosurgeries” — to exclusively commercialize and distribute its EVO® diagnostic electrodes. NMTC received a $2 million upfront payment through this partnership and a $3.5 million accelerated payment for reaching an agreed-upon milestone. For its OneRF™ system, NMTC has already placed component orders for commercialization, and it expects to launch the product either directly or with a strategic partner in the first half of 2024. Now that it has reached the commercialization stage for its electrodes, NMTC’s revenues have climbed significantly, from $171,000 in FY 2022 to $1,952,000 for FY 2023. Significantly, NMTC CFO Ronald McClurg made a big insider purchase of 50,900 shares of the company’s stock. I see a ton of strong catalysts for NMTC right now, and I am sure as you do your due diligence, you will find the same thing. No matter what you end up trading this week, I am going to emphasize that it is very important to come to the market with a solid trade plan that makes sense for you and your unique circumstances. Only trade with money you can afford to lose, and always make sure to carefully read all disclaimers and research you can get your hands on. I think NMTC is poised for big things Today is going to be an exciting day for the stock, so don’t miss out on a moment of it! To Your Success, *Sponsored content/paid advertisement. This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. 👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!). Don’t miss out! Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull DISCLAIMER *PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. for a one-day marketing program. Raging Bull was previously paid five thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NeuroOne Medical Technologies Corp. from a period beginning on December 12 through December 12, 2023. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NeuroOne Medical Technologies Corp., increased trading volume, and possibly an increased share price of NeuroOne Medical Technologies Corp.’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NeuroOne Medical Technologies Corp., though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision. SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied. [tw]( Update your email preferences or unsubscribe [here]( © 2024 Bright Ideas newsletter 62 Calef Hwy. #233 lee, NH 03861, United States of America